İbrahim Halil Tanboğa

İbrahim Halil Tanboğa

Auto-generated profile, based on publicly available information

İbrahim Halil Tanboğa

Department of Cardiology, Hisar Intercontinental Hospital Nisantasi University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2013 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Closed access
ITIbrahim Halil Tanboga
Ibrahim Halil Tanboga
STSelim Topcu
Selim Topcu
EAEnbiya Aksakal
Enbiya Aksakal
KKKamuran Kalkan
Kamuran Kalkan
SSSerdar Sevimli
Serdar Sevimli
MAMahmut Acikel
Mahmut Acikel
We aimed to investigate the determinants of angiographic thrombus burden in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (pPCI). The study population consisted of 662 patients with nonanemic STEMI who underwent pPCI. Clinical, laboratory, and demographic properties of the patients were recorded. Baseline hematologic indices were measured at the time of admission. Angiographic coronary thrombus burden was scored based on thrombolysis in myocardial infarction (TIMI) thrombus grades. After wiring and/or small balloon dilation, patients with thrombus burden grades 4 and 5 were defined as high thrombus burden, and patients with thrombus burden <grade 4 was defined as low thrombus burden. Patients with high thrombus burden had more family history of coronary artery disease, longer pain to balloon time, higher Killip class (≥II), higher neutrophil to lymphocyte ratio, red cell distribution width (RDW), baseline creatine kinase-MB fraction (CK-MB) and baseline troponin, higher peak CK-MB, and peak troponinbut lower triglycerides. Angiographically, patients with high thrombus burden had longer lesion in the infarct-related artery, less frequent direct stenting, lower epicardial and myocardial perfusion, more frequent distal embolization, and more frequent electrocardiographic and angiographic no reflow. In multivariate logistic regression analysis, only RDW (odds ratio: 1.29, 95% confidence interval 1.19-1.39, P < .001) was determined as independent predictor. The area under the receiver–operating characteristic curve of the RDW was 0.733 (0.690-0.776, P < .001) to predict high TIMI thrombus burden. Present study results demonstrated that high thrombus burden in patients with STEMI was associated with impaired postprocedural epicardial and myocardial perfusion and higher no reflow and distal embolization; and increased RDW values were independent predictors of coronary thrombus burden.

11 August 2016 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
İTİbrahim Halil Tanboğa
İbrahim Halil Tanboğa
STSelim Topçu
Selim Topçu
EAEnbiya Aksakal
Enbiya Aksakal
OGOktay Gulcu
Oktay Gulcu
EAEmrah Aksakal
Emrah Aksakal
CKCihangir Kaymaz
Cihangir Kaymaz
Recent trials reported that risk of atrial fibrillation (AF) is increased in patients using ivabradine compared with controls. We performed this meta‐analysis to investigate the risk of AF association with ivabradine treatment on the basis of data obtained from randomized controlled trials (RCTs). We searched PubMed, EMBASE, Scopus, and the Cochrane Library for RCTs that comprised >100 patients. The incidence of AF was assessed. We obtained data from European Medicines Agency (EMA) scientific reports for the RCTs in which the incidence of AF was not reported. We used trial sequential analysis (TSA) to provide information on when we had reached firm evidence of new AF based on a 15% relative risk increase (RRI) in ivabradine treatment. Three RCTs and 1 EMA overall oral safety set (OOSS) pooled analysis (included 5 RCTs) were included in the meta‐analysis (N = 40 437). The incidence of AF was 5.34% in patients using ivabradine and 4.56% in placebo. There was significantly higher incidence of AF (24% RRI) in the ivabradine group when compared with placebo before (RR: 1.24, 95% confidence interval: 1.08‐1.42, P = 0.003, I 1980 = 53%) and after excluding OOSS (RR: 1.24, 95% confidence interval: 1.06‐1.44, P = 0.008). In the TSA, the cumulative z‐curve crossed both the traditional boundary (P = 0.05) and the trial sequential monitoring boundary, indicating firm evidence for ≥15% increase in ivabradine treatment when compared with placebo. Study results indicate that AF is more common in the ivabradine group (24% RRI) than in controls.

3 July 2011 in Journal of Interventional Cardiology
Verified
Journal Article
Closed access
ITIbrahim H. Tanboga
Ibrahim H. Tanboga
MEMehmet Ekinci
Mehmet Ekinci
TITurgay Isik
Turgay Isik
MKMustafa Kurt
Mustafa Kurt
AKAhmet Kaya
Ahmet Kaya
SSSerdar Sevimli
Serdar Sevimli

14 December 2024 in Annals of Medicine
Verified
Journal Article
Open access
SASidar Şiyar AYDIN
Sidar Şiyar AYDIN
SASelim Aydemir
Selim Aydemir
MÖMurat Özmen
Murat Özmen
EAEmrah AKSAKAL
Emrah AKSAKAL
İSİbrahim Saraç
İbrahim Saraç
İTİbrahim Halil Tanboğa
İbrahim Halil Tanboğa
Heart failure (HF) remains a significant health problem despite advances in diagnosis and treatment options. Malnutrition and increased inflammation predict poor disease prognosis. The parameters of the Naples prognostic score (NPS) include albumin, total cholesterol, neutrophil-lymphocyte ratio (NLR), and lymphocyte-monocyte ratio (LMR). We aimed to assess the potential of NPS as a predictor of long-term mortality in patients with HF. A total of 1728 patients with HF who applied to our center between 2018 and 2022 were included in this study. The NPS was computed and the patients were divided into three groups according to their NPS values as follows: NPS = 0 (Group 1), NPS = 1-2 (Group 2), and NPS = 3-4 (Group 3). We also evaluated the association between NPS value and HF mortality. The patients were followed for a mean follow-up duration of 30 months. The mortality rate was 8.3% (145 patients). We carried out Model-1 and -2 Cox regression analyses to identify long-term mortality determinants. Model-2 was constructed by adding NPS to Model-1. NPS was significantly associated with HF mortality (Hazard Ratio: 2.194, 95% Confidence Interval: 1.176-4.091, p = 0.014). According to the Kaplan-Meier plot and log-rank analyses, there was a statistically significant difference in the long-term mortality of patients with HF and their NPS values for the entire cohort. Based on our findings, NPS showed promise as an independent predictor of long-term mortality in individuals with HF.

29 November 2021 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
ÖAÖzgür Yaşar Akbal
Özgür Yaşar Akbal
BKBerhan Keskin
Berhan Keskin
HTHacer Ceren Tokgöz
Hacer Ceren Tokgöz
AHAykun Hakgör
Aykun Hakgör
AKAli Karagoz
Ali Karagoz
CKCihangir Kaymaz
Cihangir Kaymaz
AngioJet rheolytic thrombectomy (ART) has been used as a catheter-based treatment for acute pulmonary embolism (PE). In this study, based on our 7-year experience with ART in patients with PE, we evaluated the efficacy and safety outcomes of ART. Our study is based on retrospective evaluation of 56 patients with high- and intermediate-high-risk PE, with an average age of 62 years [interquartile range (IQR) 50–73 years] who underwent ART. High and intermediate-high risks were noted in 21.4% and 78.6% of the patients, respectively. The ART duration was 304 (IQR: 246–468) seconds. Measures of obstruction, right to left ventricle diameter ratio, right to left atrial diameter ratio, and pulmonary arterial pressures were improved (p<0.001 for all). During the hospital stay, acute renal failure, major and minor bleeding, and mortality rates were 37.5%, 7.1%, 12.5%, and 8.9%, respectively. Aging related to post-procedural nephropathy while high-risk status was associated with in-hospital mortality (p=0.006) and long-term mortality. ART resulted in significant and clinically relevant improvements in the pulmonary arterial thrombotic burden, right ventricle strain, and hemodynamics in patients with PE at high and intermediate-high risk. Aging increased the risk of post-procedural nephropathy, whereas baseline high-risk status predicted in-hospital and long-term mortality.

2 February 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
ITIbrahim Halil Tanboğa
Ibrahim Halil Tanboğa
Ugur CanpolatUgur Canpolat
Ugur Canpolat
EÇElif Hande Özcan Çetin
Elif Hande Özcan Çetin
HKHarun Kundi
Harun Kundi
OÇOsman Çelik
Osman Çelik
STSerkan Topaloğlu
Serkan Topaloğlu
In the current study, we aimed to develop and validate a model, based on our nationwide centralized coronavirus disease 2019 (COVID‐19) database for predicting death. We conducted an observational study (CORONATION‐TR registry). All patients hospitalized with COVID‐19 in Turkey between March 11 and June 22, 2020 were included. We developed the model and validated both temporal and geographical models. Model performances were assessed by area under the curve‐receiver operating characteristic (AUC‐ROC or c‐index), R2, and calibration plots. The study population comprised a total of 60,980 hospitalized COVID‐19 patients. Of these patients, 7688 (13%) were transferred to intensive care unit, 4867 patients (8.0%) required mechanical ventilation, and 2682 patients (4.0%) died. Advanced age, increased levels of lactate dehydrogenase, C‐reactive protein, neutrophil–lymphocyte ratio, creatinine, albumine, and D‐dimer levels, and pneumonia on computed tomography, diabetes mellitus, and heart failure status at admission were found to be the strongest predictors of death at 30 days in the multivariable logistic regression model (area under the curve‐receiver operating characteristic = 0.942; 95% confidence interval: 0.939–0.945; R2 = .457). There were also favorable temporal and geographic validations. We developed and validated the prediction model to identify in‐hospital deaths in all hospitalized COVID‐19 patients. Our model achieved reasonable performances in both temporal and geographic validations.